SCHEMBL14720839

SCHEMBL14720839

CONC(=O)C(c1ccc(Br)cc1F)N1CCC2(CC1)CN(C1CC1)C(=O)CO2

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FASN P49327 4/20 0.34
OPRM1 P35372 4/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
APLNR P35414 2/20 0.32
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
MAPK1 P28482 1/20 0.31
CYP2C19 P33261 1/20 0.31
AAK1 Q2M2I8 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD11B1 P28845 1/20 0.30
AADAT Q8N5Z0 1/20 0.30
MAP2K1 Q02750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14720433 0.92 FASN (0.36) FASNOPRM1CNR1CNR2APLNR
SCHEMBL14720420 0.91 FASN (0.36) FASNOPRM1CNR1CNR2HSD11B1
SCHEMBL14720613 0.88 FASN (0.37) FASNOPRM1CNR1CNR2HSD11B1
SCHEMBL14720349 0.87 FASN (0.38) FASNOPRM1CNR1CNR2HSD11B1
SCHEMBL14720239 0.84 FASN (0.36) FASNOPRM1CNR1CNR2ALDH1A1
SCHEMBL14720191 0.83 OPRM1 (0.46) FASNOPRM1APLNRHSD11B1
SCHEMBL14720432 0.82 FASN (0.56) FASN
SCHEMBL14720419 0.81 FASN (0.36) FASNOPRM1CNR1CNR2MEN1
SCHEMBL14720861 0.79 FASN (0.37) FASN
SCHEMBL14720343 0.79 FASN (0.42) FASNALDH1A1CYP3A4CYP2D6MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2744333-B1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-10-05 EP disclosed
US-9084794-B2 Fatty acid synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2015-07-21 US disclosed
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property (No2) Limite (GB) 2014-07-10 US disclosed
EP-2744333-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-06-25 EP disclosed
WO-2013028447-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS2, FADS1 FASN 1/4885OPRM1 3162/4885CNR1 1289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.